SIRT4 enhances the sensitivity of ER‐positive breast cancer to tamoxifen by inhibiting the IL‐6/STAT3 signal pathway

Recent advances in endocrine therapy have improved the prospects for estrogen receptor‐positive breast cancer. Tamoxifen is an effective drug for patients with estrogen receptor‐positive breast cancer, but the development of resistance is common. Therefore, discovering ways to enhance the sensitivit...

Descripción completa

Detalles Bibliográficos
Autores principales: Xing, Jilin, Li, Ji, Fu, Lin, Gai, Junda, Guan, Jingqian, Li, Qingchang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Cancer Biology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6853819/
https://www.ncbi.nlm.nih.gov/pubmed/31573734
http://dx.doi.org/10.1002/cam4.2557

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6853819/
https://www.ncbi.nlm.nih.gov/pubmed/31573734
http://dx.doi.org/10.1002/cam4.2557

Ejemplares similares